Diabetes Mellitus Type 2

Reducing HF Hospitalization Risk: Antidiabetic Drug Classes Compared

By September 11, 2018

The authors searched for randomized placebo-controlled trials (December 1, 2008 to November 24, 2017) involving 3 pharmacologic classes of antidiabetic medications to compare the effects of these agents on the risk of hospitalization for HF in T2DM patients.

FDA: Cases of Rare Gangrene of Genital Area Tied to Diabetes Drug Class

By August 30, 2018

The infection developed within several months of the patients starting SGLT2 therapy and the drug was discontinued in most cases. All patients required surgery and there was 1 reported death.

Oral Semaglutide Appears Safe, Effective in T2D Patients With Renal Impairment

By August 20, 2018

PIONEER 5 (N=324) was a randomized, double-blind, placebo-controlled, parallel-group, 26-week trial that evaluated the safety and efficacy of oral semaglutide 14mg vs placebo in patients with type 2 diabetes and moderate renal impairment (eGFR 30 to 59mL/min/1.73m2) inadequately controlled with metformin, sulfonylurea alone or in combination with metformin, or basal insulin alone or in combination with metformin.

FDA Approves FreeStyle Libre 14 Day Flash Glucose Monitoring System

By July 30, 2018

The new Flash Glucose Monitoring System enables patients to wear the sensor for up to 14 days compared with the existing FreeStyle Libre System that was approved for 10-day wear.

New Data Support Long-Term Cardiovascular Safety of Linagliptin in T2D

By July 19, 2018

Results showed the overall safety profile of linagliptin in study patients, including adults with kidney disease, was consistent with previous data.

FDA Clears Omnipod DASH System for Diabetes Management

By June 05, 2018

The Omnipod DASH system consists of a discreet, tubeless, waterproof Pod which is worn on the body, and the Personal Diabetes Manager (PDM), a handheld wireless device used to control the Pod.

SGLT2 Inhibitors Canagliflozin, Dapagliflozin Compared in Real-World Study

By April 27, 2018

Researchers performed a retrospective cohort study by identifying patients from the Optum Clinformatics database who were initiated on canagliflozin 300mg or dapagliflozin 100mg from January 1, 2014 to September 30, 2016.

Canagliflozin May Improve Renal Outcomes in Patients With T2D

By April 12, 2018

The renal protective benefit was seen in patients with both reduced (eGFR <60mL/min/1.73m2) and preserved (eGFR ≥60mL/min/1.73m2) renal function.

Bydureon Approved for Use With Basal Insulin for Uncontrolled T2D

By April 03, 2018

The DURATION-7 study examined the effect of Bydureon or placebo as add-on therapy to insulin glargine, with or without metformin, in adults with T2D.

Dapagliflozin Evaluated in Patients With T2D and Moderate Renal Impairment

By March 20, 2018

Farxiga is a sodium-glucose co-transporter 2 (SGLT2) inhibitor currently indicated as an adjunct to diet and exercise to improve glycemic control in adults with T2D mellitus.

Fenofibrate Treatment Effect Varies in Patients With T2DM

February 27, 2018

Treatment effect is greater in patients with dyslipidemia; absolute risk reduction of 2.15 percent

Sudden Cardiac Arrest, Ventricular Arrhythmia Risk Examined With Sulfonylureas

By February 16, 2018

Using U.S. Medicaid claims (1999-2010) from 5 states, the researchers sought to examine the association between individual sulfonylureas (glyburide, glimepiride, glipizide) and outpatient-originating SCA/VA; glipizide exposure was considered the reference exposure.

Ozempic, Fiasp Now Available for the Treatment of Diabetes

By February 05, 2018

Both medications received approval from the FDA in 2017.

Semaglutide Goes Head-to-Head With Dulaglutide in Type 2 Diabetes Trial

By February 01, 2018

The overall safety profiles of semaglutide and dulaglutide were similar in SUSTAIN 7.

Update Regarding Tanzeum Injection Availability

By January 26, 2018

The initial decision to discontinue Tanzeum was announced in August 2017 due to limited prescribing of the drug.

Bydureon BCise Now Available for the Treatment of Type 2 Diabetes

By January 10, 2018

Bydrueon BCise is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Three New Type 2 Diabetes Treatments Get FDA Approval

By December 26, 2017

Steglatro, Steglujan, and Segluromet have all received FDA approval for the treatment of type 2 diabetes.

First Short-Acting Insulin Approved as a "Follow-On" Product

By December 11, 2017

The use of abbreviated pathways can reduce drug development costs so products can be offered at a lower price to patients.

Ozempic Approved to Treat Adults With Type 2 Diabetes

By December 05, 2017

The global Phase 3a clinical trial program for Ozempic comprised 8 clinical trials involving more than 8,000 adults with type 2 diabetes.

Serious Hypoglycemia Risk Compared Among Oral Antidiabetics

By November 07, 2017

Among all study drugs, the highest rate was seen with glyburide.

Bydureon BCise Gets FDA Approval for Type 2 Diabetes

By October 23, 2017

In clinical trials, treatment with Bydureon BCise resulted in average HbA1c reductions of up to 1.4% and average weight loss of up to 3.1 pounds when used as monotherapy or as an add-on to metormin, a sulfonylurea, a thiazolidinedione, or any combination of two of these agents, at 28 weeks.

FDA Committee Supports Semaglutide Approval for Type 2 Diabetes

By October 19, 2017

The FDA Committee's positive recommendation was based on data from the global development program, SUSTAIN, which evaluated the safety and efficacy of once-weekly semaglutide.

Do SGLT2 Inhibitors Raise the Risk of Lower Extremity Amputation?

By September 15, 2017

Study authors analyzed the occurrence of amputation in patients with type 2 diabetes mellitus treated with SGLT2 inhibitors vs. non-SGLT2 inhibitors, and specifically, canagliflozin.

ACP: Updated Drug Therapy Recommendations for T2DM

By January 03, 2017

The update was prompted following new research evaluating medications for type 2 diabetes.

ADA Issues Guidelines for Psychosocial Care in Diabetes

By November 23, 2016

The American Diabetes Association (ADA) released its first position statement that includes detailed guidelines for psychosocial assessments and care based on factors including age, type of diabetes, and family support system.